伊马替尼治疗后慢性粒细胞白血病患者出现新的JAK2V617F克隆并随后发展为明显的真性红细胞增多症。 - Suppr

Suppr

超能文献

Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.

作者信息

Tefferi Ayalew, Levitt Ralph, Lasho Terra L, Knudson Ryan A, Ketterling Rhett P

出版信息

Eur J Haematol. 2010 Jul;85(1):86-7. doi: 10.1111/j.1600-0609.2010.01458.x. Epub 2010 Apr 16.

DOI:10.1111/j.1600-0609.2010.01458.x

PMID:20408872

Abstract

摘要

相似文献

Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.

Eur J Haematol. 2010 Jul;85(1):86-7. doi: 10.1111/j.1600-0609.2010.01458.x. Epub 2010 Apr 16.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21.

BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.

Blood. 2013 Feb 14;121(7):1238-9. doi: 10.1182/blood-2012-11-467787.

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

Leukemia. 2007 May;21(5):1103-4. doi: 10.1038/sj.leu.2404591. Epub 2007 Feb 15.

[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].

Rinsho Ketsueki. 2014 Jun;55(6):687-91.

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12.

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77.

Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.

J Dermatol. 2007 Oct;34(10):724-6. doi: 10.1111/j.1346-8138.2007.00369.x.

A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

Ann Hematol. 2023 May;102(5):1279-1280. doi: 10.1007/s00277-023-05187-5. Epub 2023 Mar 22.

Emergence of Chronic Myeloid Leukemia in a -V617F Polycythemia Vera.

J Hematol. 2020 Apr;9(1-2):23-29. doi: 10.14740/jh591. Epub 2020 Apr 23.

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):633-635. doi: 10.1007/s12288-017-0781-4.

Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):331-4. doi: 10.1007/s12288-014-0385-1. Epub 2014 Apr 11.

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.

Exp Hematol Oncol. 2013 Sep 5;2(1):24. doi: 10.1186/2162-3619-2-24.

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Int J Hematol. 2013 Jun;97(6):804-7. doi: 10.1007/s12185-013-1326-8. Epub 2013 Apr 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验